aria is by far and away my favorite biotech longterm.
but for the longterm amrn and tsrx i have accumulated and still am
amrn has pdufa date july 26. best in class product and one that big pharma needs. if your patient it will do very well. avg is 6 looking for 30 in 2 years
tsrx is low cap stock with that just needs catalysts to come this fall and it will. good safe drug here. very undervalued.
Its strictly high risk investing for casino money only. The story is fascinating. They have technology to insert or remove any gene in any cell in any animal or plant. Game changing.
Currently working on HIV cure. Cure not treatment. Monogenetic disease targets are on the plate. Good partnerships with agro companies.
The story is so exciting one can easily fail to notice that they have been churning around with this technology for a decade. I own it mainly to keep up with this biotech field.